首页 › 三阴性乳腺癌 › 密歇根州 › Grand Rapids
Grand Rapids MI 三阴性乳腺癌临床试验
15项针对 三阴性乳腺癌的研究正在 Grand Rapids及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
招募中1 期
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
招募中1/2 期
- BAMF Health, Grand Rapids
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
招募中3 期
- Cancer & Hematology Centers of Western Michigan ( Site 0026), Grand Rapids
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
招募中1 期
- BAMF Health, Grand Rapids
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
招募中1 期
- START Midwest, Grand Rapids
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
招募中3 期
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
招募中1 期
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
招募中1/2 期
- Research Site, Grand Rapids
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
招募中1/2 期
- START Midwest, Grand Rapids
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- START Midwest, Grand Rapids
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
招募中1 期
- BAMF Health, Grand Rapids
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
招募中1 期
- START Midwest, LLC, Grand Rapids
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- START Midwest /ID# 248685, Grand Rapids
其他城市的 三阴性乳腺癌试验
- Houston, TX42 项研究
- New York City, NY31 项研究
- Nashville, TN28 项研究
- Los Angeles, CA27 项研究
- Boston, MA26 项研究
- San Antonio, TX23 项研究
- St. Louis, MO21 项研究
- Arlington, VA20 项研究
- Atlanta, GA20 项研究
- Dallas, TX18 项研究
- Chicago, IL16 项研究
- Columbus, OH16 项研究
Grand Rapids的其他研究
- 非小细胞肺癌44 项研究
- 结直肠癌40 项研究
- 癌症（所有类型）28 项研究
- 乳腺癌26 项研究
- 卵巢癌24 项研究
- 转移性癌症22 项研究
- 前列腺癌19 项研究
- 子宫内膜癌18 项研究
- 胃癌18 项研究
- 胰腺癌18 项研究
- 黑色素瘤17 项研究
- 头颈鳞状细胞癌15 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。